CN104193699B - 一种小分子化合物及其合成方法和应用 - Google Patents
一种小分子化合物及其合成方法和应用 Download PDFInfo
- Publication number
- CN104193699B CN104193699B CN201410398184.1A CN201410398184A CN104193699B CN 104193699 B CN104193699 B CN 104193699B CN 201410398184 A CN201410398184 A CN 201410398184A CN 104193699 B CN104193699 B CN 104193699B
- Authority
- CN
- China
- Prior art keywords
- chloro
- bis
- phenyl
- oxalyl
- azanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000010189 synthetic method Methods 0.000 title claims description 11
- -1 methoxyl group Chemical class 0.000 claims description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 18
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 14
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000003368 amide group Chemical group 0.000 claims description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 7
- KMAQZIILEGKYQZ-UHFFFAOYSA-N 1-chloro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Cl)=C1 KMAQZIILEGKYQZ-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 claims description 4
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 230000017858 demethylation Effects 0.000 claims description 4
- 238000010520 demethylation reaction Methods 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- HHLCSFGOTLUREE-UHFFFAOYSA-N 1,2,3-trichloro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Cl)C(Cl)=C1 HHLCSFGOTLUREE-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical class 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims description 2
- YNXURHRFIMQACJ-UHFFFAOYSA-N lithium;methanidylbenzene Chemical compound [Li+].[CH2-]C1=CC=CC=C1 YNXURHRFIMQACJ-UHFFFAOYSA-N 0.000 claims description 2
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- KCWYOFZQRFCIIE-UHFFFAOYSA-N ethylsilane Chemical compound CC[SiH3] KCWYOFZQRFCIIE-UHFFFAOYSA-N 0.000 claims 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 108010048734 sclerotin Proteins 0.000 claims 1
- 230000003779 hair growth Effects 0.000 abstract description 40
- 230000012010 growth Effects 0.000 abstract description 16
- 210000004209 hair Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 238000012360 testing method Methods 0.000 description 26
- 238000001228 spectrum Methods 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 238000010586 diagram Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 0 CCCC(C)CC(C(C)=C(C)[C@](CC)CC12C3C1C3C(C*)C2)=C Chemical compound CCCC(C)CC(C(C)=C(C)[C@](CC)CC12C3C1C3C(C*)C2)=C 0.000 description 5
- 208000001840 Dandruff Diseases 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 238000011735 C3H mouse Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229950005499 carbon tetrachloride Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000001119 stannous chloride Substances 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000030695 Sparse hair Diseases 0.000 description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003781 hair follicle cycle Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229960002613 tamsulosin Drugs 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- NBCQLWNLTLMGCB-UHFFFAOYSA-N 1-(4-methoxyphenoxy)-4-nitrobenzene Chemical compound C1=CC(OC)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1 NBCQLWNLTLMGCB-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CZGCEKJOLUNIFY-UHFFFAOYSA-N 4-Chloronitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1 CZGCEKJOLUNIFY-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- HQLZFBUAULNEGP-LURJTMIESA-N CCC[C@H](CC)N Chemical compound CCC[C@H](CC)N HQLZFBUAULNEGP-LURJTMIESA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000699667 Mus spretus Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/22—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups esterified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
Abstract
本发明提供了一种小分子化合物,其特征在于,由如下结构式所示:本发明产品的各种浓度剂量均能明显的改变毛发生长周期,促进毛发生长。表现出了明显的毛发生长促进效果。此外,每组中的小鼠体重变化的都很缓慢,表明受试化合物不会引起动物体重减少。
Description
技术领域
本发明涉及化学合成领域,特别地,是涉及一种小分子化合物及其合成方法和应用。
背景技术
毛囊是一个不断重复三个生长阶段:毛发生长初期(生长期)、毛发生长中期(退化期)和毛发生长终期(休眠期)的微小器官。在生长期,毛球角化细胞(HBK)剧烈的增值和分化,导致毛干的生长延长。
目前,研究报道了许多生物学因子对毛发周期的调节和同步有作用。这些因子可以被划分为不同的类别,例如,激素,生长因子,酶和转录因子。具体地说,如、利用基因敲除和转基因鼠的研究标明,音猬因子和角质化细胞生长因子促进毛发生长初期的开始,转化生长因子-β,成纤维细胞生长因子-5和神经生长因子通过诱导HBK凋亡,加速毛囊由生长初期向生长中期转化。正常状态下,毛囊周期可以被这些因子很好的调控。
然而,研究表明,针对有压力或者雄性激素的病理学刺激可能会导致毛囊周期紊乱,包括生长初期的缩短,生长终期的延长,从而导致脱发等问题的产生。
迄今为止,市场上也出现了部分针对性的药剂,尤其是FDA通过的两个药:米诺地尔和非那司提。米诺地尔最早用于高血压的治疗,治疗过程中发现几乎所有使用米诺地尔的患者都出现了多毛症的症状。1996年,2%的米诺地尔溶液被通过作为雄性激素引起的秃发症的非处方药。非那司提是FDA通过的唯一一个用于临床的治疗秃发症的药物,是5α-还原酶抑制剂。它能抑制5α-还原酶(II型)活性,从而阻止毛发中***转化为二氢***(DHT),降低了脱发区DHT的量(促进毛发生长)。
然而随着时代的发展,关于毛发上的病症越来越凸现,因此,为了符合现代人的需求,对于相关药品的多元化和多样性的研究,有待进一步的深入和展开。
发明内容
本发明旨在研究一种能够应用于毛发生长的新药品。
一种小分子化合物,其特征由如下结构式所示:
R1选自氢、卤素、C0-C6的烷基或其任意地被一个到三个取代基取代、氰基、异氰酸酯基、酰胺基、异磺酰胺基、异亚磺酰胺基、磺酰胺基、亚磺酰胺基、S-烷基、S-芳基、S-芳杂基,
其中,所述取代基选自于卤素、芳基、取代芳基、杂芳基、O-烷基、O-芳基、O-芳杂基、N-烷基、N-芳基、N-杂芳基;
R2选自氢、卤素、C0-C6的烷基或取代烷基、烷氧基、芳基、取代芳基、苄基、取代苄基;
R3选自氢、卤素、C0-C6的烷基或取代烷基、烷氧基、芳基、取代芳基、苄基、取代苄基;
R4选自氢、C1-C6的烷基或取代烷基;
R5选自氢、C0-C6的烷基或取代烷基;
X选自烷基或取代烷基、胺基或取代胺基;
Y选自烷基或取代烷基、氧、硫、氨基、羰基、亚砜基、砜基。
本发明所提供的小分子化合物,可优选地由如下结构式所示:
其中,R为单取代或多取代的卤素、烷基磺酰基、烷基、甲氧基、硝基、氨基、羧基、酯基、羟基、芳基、苄基、氢。
本发明提供的小分子化合物更优选为:
N1-(3,5-二氯-4-(3-(4-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(3-(4-甲磺酰基苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(3-(4-甲基苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(3-(3,4-二氯苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(3-(3-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(3-(2-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(4-羟基-3-(甲基吗啉)苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(4-羟基-3-(4-羟基哌啶-1-基)苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(4-羟基-3-(4-甲基哌嗪-1-甲基)苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(4-羟基-3-(吡咯烷-1-甲基)苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(4-(3-((4-苄基哌啶-1-甲基)-4-羟基苯氧基)-3,5-二氯苯基)N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(4-羟基-3-((4-羟基-4-苯基哌啶-1-甲基)苯氧基)苯基)N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(4-羟基-3-(异吲哚啉-2-甲基)苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(3-(3,4-二氢异喹啉-2(1H)-甲基)-4-羟基苯氧基)苯基)-N2-草酰羟胺,其结构式为:
N1-(3,5-二氯-4-(4-羟基-3-(3-哌嗪酮-1-甲基)苯氧基)苯基)-N2-草酰羟胺,其结构式为:
本发明还提供了上述一种小分子化合物的合成方法,其特征在于:采用4-甲氧基苯酚和1,2,3-三氯-5-硝基苯为初始原料。
具体的合成步骤如下所示:
步骤一、通过4-甲氧基苯酚与1,2,3-三氯-5-硝基苯反应生成1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯;
步骤二、将1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯与苯甲酸衍生物反应生成(5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(取代苯基)甲基酮;
步骤三、将(5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(取代苯基)甲基酮的羰基还原为亚甲基、硝基还原为氨基后得到3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯胺;
步骤四、将3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯胺与草酰氯单乙酯反应生成2-((3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯;
步骤五、将2-((3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯与盐酸羟胺反应生成N1-(3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)-N2-草酰羟胺;
步骤六、将N1-(3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)-N2-草酰羟胺上的甲氧基脱甲基后获得目标小分子化合物。
上述工艺步骤的反应方程式如下所示:
其中,步骤一在强碱条件下进行,强碱与4-甲氧基苯酚的摩尔比为1.5-2:1。该强碱可选自有机/无机的各类可应用于该成醚反应的各类强碱试剂。优选自氨基钾、氨基钠、***、***、丁基锂、二异丙基氨锂、苄基锂、格氏试剂,烷基铜锂、甲醇钠、乙醇钠、乙醇钾、叔丁醇钠、氢氧化钠、氢氧化钾等中的任一一种,反应温度为120-160℃,反应时间为1-6小时。
此外,该反应优选在DMF及其物理/化学性质相类似的溶剂中进行,反应物4-甲氧基苯酚与1,2,3-三氯-5-硝基苯的摩尔比为1:1-2。1,2,3-三氯-5-硝基苯优选在4-甲氧基苯酚与碱剂混合搅拌均匀(一般为30-60分钟)后再加入。
步骤二在伊顿试剂中进行,反应温度为80-130℃,反应时间为2-8小时。1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯与苯甲酸衍生物的摩尔比为1:1.25-2;。
步骤三的目的在于将羰基还原为亚甲基,在本发明中,优选采用三氟乙酸和三乙基硅烷将羰基还原为亚甲基,当使用上述还原剂时,5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(取代苯基)甲基酮:三氟乙酸:三乙基硅烷的摩尔比为1:4-6:3-5,溶剂优选使用二氯甲烷、三氯甲烷、四氯甲烷等,该反应在室温下进行,优选反应时间为1-6小时。
步骤四的目的在于将硝基还原为胺基,在本发明中,还原剂可使用氯化亚锡、铁、锌、Pt、Ni等还原用的制剂。5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(取代苯基)甲基酮与还原剂的摩尔比为1:10-20。回流反应1-6小时。
步骤五中3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯胺与草酰氯单乙酯的摩尔比为1:1.5-3;草酰氯单乙酯和三乙胺的摩尔比为1:1.3-2.3。反应0.5-3小时。
步骤六中2-((3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯与盐酸羟胺的摩尔比为1:5-10,盐酸羟胺与碱(如:氢氧化钠)的摩尔比为1:1。反应8-14小时。
步骤七中的脱甲基可采用三氯化铝、氯化锌、三溴化硼进行。每50mg原料使用的脱甲基剂为1-5滴(约1-20mg),反应1-5小时。
上述各步骤中,采用的溶剂可以为氯仿、二氯甲烷、四氯甲烷、乙酸乙酯、乙酸甲酯、甲苯、苯、氯苯、DMF、二氧六环、乙醇、丙酮等。
此处值得指出的是,在本发明中,根据本发明的化合物及其衍生物的分子结构,任何常规合成手段都可以用来合成该物质。上述具体合成路线仅为手段之一。
本发明提供的上述一种小分子化合物,其特征在于:可应用于毛发生长、骨质疏松症、肥胖等病症,特别是针对毛发的再生长,可用于针对性的治疗雄性激素型秃发的问题。
本发明的作用和效果
本发明合成了一种新型的物质,可以用于毛发的再生长。
经皮给药小鼠毛发生长试验发现,本发明产品的各种浓度剂量均能明显的改变毛发生长周期,促进毛发生长。表现出了明显的毛发生长促进效果。此外,每组中的小鼠体重变化的都很缓慢,表明受试化合物不会引起动物体重减少。
从上述结果可以知道,该物质无毒副作用,且增毛效果明显。
附图说明
附图1(a)、TDM-001-1中小鼠毛发生长照片;
附图1(b)、TDM-001-2中小鼠毛发生长照片;
附图1(c)、TDM-001-3中小鼠毛发生长照片;
附图1(d)、TDM-001-4中小鼠毛发生长照片;
附图2、TMI-105795的试验结果;
附图3、TMI-105902的试验结果;
附图4、TMI-105903的试验结果;
附图5、TMI-105905的试验结果;
附图6、TMI-105965的试验结果;
附图7、TMI-105966的试验结果;
附图8、TMI-105906的试验结果;
附图9、TMI-105956的试验结果;
附图10、TMI-105957的试验结果;
附图11、TMI-105958的试验结果;
附图12、TMI-105959的试验结果;
附图13、TMI-105960的试验结果;
附图14、TMI-105961的试验结果;
附图15、TMI-105962的试验结果;
附图16、TMI-105963的试验结果;
附图17、给药过程中体重的变化曲线图;
附图18、给药过程中毛发生长评分曲线图;
附图19、给药过程中皮屑评分曲线图;
附图20、给药过程中红斑评分曲线图。
具体实施例
实施例一、产品编号TMI-105795
命名:
N1-(3,5-二氯-4-(3-(4-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺
结构式:
合成路线:
具体合成方法:
步骤1:1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯的合成
把4-甲氧基苯酚(5.5克,44mmol)溶于DMF(100mL)加入NaH(2.64克,66mmol),搅拌半个小时后加入1,2,3-三氯-5-硝基苯(10克,44mmol)。反应液加热到120℃三个小时。反应结束和冷却到室温,然后浓缩。剩余物用水淬灭后用乙酸乙酯萃取。有机层干燥浓缩后得到粗产品,然后柱层析(0-10%乙酸乙酯和石油醚)得到产物(5.0克,36%)。
在本步骤中,尝试选用了不同的反应条件。如:原料比(4-甲氧基苯酚:NaH:1,2,3-三氯-5-硝基苯=1:2:1或1:1.8:1.5等不同比例)、溶剂(氯苯,二氧六环等)、碱剂(NaH、NaOH、叔丁醇纳等)、反应的温度(130℃,160℃),反应时间(1小时、2小时、4小时、5小时、6小时等),得到的产品得率从31%-68%不等。
步骤2:(5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(4-氟苯基)甲基酮的合成
把1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯(5.0克,16mmol),4-氟苯甲酸(2.8克,20mmol)分散在伊顿试剂中(30mL),然后把这个混合物加热到80℃四个小时。反应液冷却到室温,用碳酸氢钠的水溶液淬灭。水相用乙酸乙酯萃取,无水Na2SO4干燥后浓缩。剩余物柱层析(10%乙酸乙酯和石油醚)后得到产物(4.5克,64%)。
在本步骤中,尝试选用了不同的反应条件。如:原料比(1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯:4-氟苯甲酸=1:1、1:1.5、1:2等),反应温度(100℃、110℃、130℃等),反应时间(2小时,5小时,8小时等),得到的产品得率从56%-78%不等。
步骤3:1,3-二氯-2-(3-(4-氟苄基)-4-甲氧基苯氧基)-5-硝基苯的合成
把(5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(4-氟苯基)甲基酮(4.4克,10mmol)溶于二氯甲烷(50mL)加入三氟乙酸(6.0克,40mmol)和三乙基硅烷(3.5克,30mmol).反应液在室温搅拌三个小时,然后用碳酸氢钠的水溶液淬灭。水相用乙酸乙酯萃取,无水Na2SO4干燥后浓缩。剩余物柱层析后(10%乙酸乙酯和石油醚)得到产物(3.5克,83%)。
在本步骤中,尝试选用了不同的反应条件。如:原料比((5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(4-氟苯基)甲基酮:三氟乙酸:三乙基硅烷=1:4:3、1:5:4、1:6:5等),溶剂为(氯仿、氯苯、甲苯等),反应时间(1小时,2小时,6小时等),得到的产品得率从80%-96%不等。
步骤4:3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯胺的合成
把1,3-二氯-2-(3-(4-氟苄基)-4-甲氧基苯氧基)-5-硝基苯(3.5克,8.3mmol)溶于乙酸乙酯(50mL)中,加入氯化亚锡(18.7克,83mmol),然后加热回流三个小时。反应液冷却到室温,用碳酸氢钠的水溶液调节到pH-8,然后过滤萃取。萃取液浓缩后得到产品(2.6克,81%)。
在本步骤中,尝试选用了不同的反应条件。如:原料比(1,3-二氯-2-(3-(4-氟苄基)-4-甲氧基苯氧基)-5-硝基苯:氯化亚锡=1:10、1:15、1:20等),溶剂为(乙酸甲酯、丙酮、苯等),还原剂(Zn/HCl、Pt/H2、Ni/H2等),反应时间(1小时,2小时,6小时等),得到的产品得率从80%-99%不等。
步骤5:2-((3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯的合成
把3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯胺(200毫克,0.51mmol)溶于二氯甲烷,加入草酰氯单乙酯(120毫克,0.76mmol)和三乙胺(100毫克,1.02mmol)。反应液搅拌一个小时后,用碳酸氢钠的水溶液淬灭。水相用二氯甲烷萃取,有机层用饱和食盐水洗,然后用Na2SO4干燥浓缩后得到产品(250毫克,100%)。
在本步骤中,尝试选用了不同的反应条件。如:原料比(3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯胺:草酰氯单乙酯的摩尔比=1:1.5、1:2、1:2.3、1:3等,草酰氯单乙酯:三乙胺的摩尔比=1:1.5、1:2、1:2.3),溶剂为(氯仿、乙酸乙酯、氯苯等),反应时间(0.5小时,2小时,3小时等),得到的产品得率从90-100%不等。
步骤6:N1-(3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯基)-N2-草酰羟胺的合成
把2-((3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯(50毫克,0.10mmol),盐酸羟胺(35毫克,0.5mmol)和氢氧化钠(20毫克,0.5mmol)溶于乙醇(10mL)中,反应液在室温搅拌过夜。反应液浓缩后用乙酸乙酯萃取,干燥浓缩后得到产品(50毫克,100%)。
在本步骤中,尝试选用了不同的反应条件。如:原料比(2-((3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯:盐酸羟胺:氢氧化钠的摩尔比=1:4:4、1:6:6、1:8:8、1:10:10等),溶剂为(乙酸乙酯、甲醇等),反应时间(8小时,10小时,12小时,14小时,16小时,18小时等),得到的产品得率从90-100%不等。
步骤7:N1-(3,5-二氯-4-(3-(4-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺的合成
把N1-(3,5-二氯-4-(3-(4-氟苄基)-4-甲氧基苯氧基)苯基)-N2-草酰羟胺(50毫克,0.1mmol)溶于二氯甲烷,加入两滴三溴化硼。反应液搅拌三个小时,用甲醇淬灭后浓缩。剩余物分散在乙酸乙酯和水中,乙酸乙酯层浓缩后加入正己烷析出产品(6毫克,12%)。
在本步骤中,尝试选用了不同的反应条件。如:三溴化硼(1mg、5mg、10mg、15mg、20mg等),溶剂为(氯苯、氯仿、四氯甲烷等),反应时间(1小时,2小时,5小时等),得到的产品得率从4-30%不等。
产物谱图数据:
核磁氢谱(氘代甲醇)δ7.92(s,2H),7.19(dd,J=8.7,5.5Hz,2H),6.96(t,J=8.9Hz,2H),6.71(d,J=9.1Hz,1H),6.44-6.51(m,2H),3.87(s,2H)
质谱:m/z465.3[M+H]+
下述实施例二至六所采用的合成方法与实施例一相似或相近,故,此处不再做冗余的描述。
实施例二、产品编号TMI-105902
命名:
N1-(3,5-二氯-4-(3-(4-甲磺酰基苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
核磁氢谱(氘代甲醇)δ7.92(s,2H),7.83(d,J=8.6Hz,2H),7.47(d,J=8.3Hz,2H),6.73(d,J=9.4Hz,1H),6.49-6.57(m,2H),4.02(s,2H),3.10(s,3H)
质谱:m/z523.6[M-H]-
实施例三、产品编号TMI-105903
命名:
N1-(3,5-二氯-4-(3-(4-甲基苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
核磁氢谱(氘代甲醇)δ7.90(s,2H),7.05(s,4H),6.70(d,J=8.6Hz,1H),6.43-6.49(m,1H),6.39(d,J=3.0Hz,1H),3.84(s,2H),2.29(s,3H)
质谱:m/z459.6[M-H]-
实施例四、产品编号TMI-105905
命名:
N1-(3,5-二氯-4-(3-(3,4-二氯苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
核磁氢谱(氘代甲醇)δ7.93(s,2H),7.38(d,J=8.1Hz,1H),7.32(d,J=1.9Hz,1H),7.12(dd,J=8.2,2.0Hz,1H),6.73(d,J=8.6Hz,1H),6.52-6.58(m,1H),6.50(d,J=3.0Hz,1H),3.87(s,2H)
质谱:m/z513.5[M-H]-
实施例五、产品编号TMI-105965
命名:
N1-(3,5-二氯-4-(3-(3-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
核磁氢谱(氘代甲醇)δ7.91(s,2H),7.11-7.24(m,2H),6.98-7.08(m,2H),6.71(d,J=8.6Hz,1H),6.48(dd,J=8.6,3.2Hz,1H),6.42(d,J=3.0Hz,1H),3.91(s,2H)
质谱:m/z463.5[M-H]-
实施例六、产品编号TMI-105966
命名:
N1-(3,5-二氯-4-(3-(2-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
核磁氢谱(氘代甲醇)δ7.91(s,2H),7.12-7.24(m,2H),7.00-7.10(m,2H),6.71(d,J=8.6Hz,1H),6.48(dd,J=8.7,3.1Hz,1H),6.42(d,J=3.0Hz,1H),3.91(s,2H)
质谱:m/z463.5[M-H]-
实施例七、产品编号TMI-105906
命名:
N1-(3,5-二氯-4-(4-羟基-3-(甲基吗啉)苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:10.99(br.s.,1H),9.83(br.s.,2H),8.95(s,1H),7.96-8.22(m,2H),7.60-7.73(m,1H),6.64-6.72(m,2H),6.51-6.60(m,1H),3.57(br.s.,4H),3.52(s,2H),2.40(br.s.,4H)
实施例八、产品编号TMI-105956
命名:
N1-(3,5-二氯-4-(4-羟基-3-(4-羟基哌啶-1-基)苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:10.10(br.s.,1H),8.10(s,3H),6.58-6.73(m,2H),6.53(d,J=8.3Hz,1H),4.62(br.s.,1H),3.37(br.s.,2H),2.69(br.s.,2H),2.14(br.s.,2H),1.72(d,J=9.4Hz,2H),1.38(d,J=9.1Hz,2H)
实施例九、产品编号TMI-105957
命名:
N1-(3,5-二氯-4-(4-羟基-3-(4-甲基哌嗪-1-甲基)苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:11.01(br.s.,1H),8.06-8.14(m,2H),6.60-6.70(m,2H),6.54(dd,J=8.7,3.1Hz,1H),3.34(br.s.,2H),2.42(br.s.,4H),2.18-2.38(m,4H),2.11-2.18(m,3H)
实施例十、产品编号TMI-105958
命名:
N1-(3,5-二氯-4-(4-羟基-3-(吡咯烷-1-甲基)苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:10.90(br.s.,1H),10.77(br.s.,1H),8.11(br.s.,2H),6.87(br.s.,1H),6.64(br.s.,2H),6.53(br.s.,2H),3.45(d,J=5.4Hz,2H),1.72(br.s.,4H),1.06(br.s.,2H)
实施例十一、产品编号TMI-105959
命名:
N1-(4-(3-((4-苄基哌啶-1-甲基)-4-羟基苯氧基)-3,5-二氯苯基)N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(METHANOL-d4)δ:8.40(br.s.,1H),7.99(s,2H),7.51(d,J=7.3Hz,2H),7.38(t,J=7.5Hz,2H),7.30(d,J=7.5Hz,1H),6.87-6.98(m,2H),6.82-6.87(m,1H),4.34(s,2H),3.38-3.52(m,4H),2.28-2.41(m,2H),1.96(d,J=14.2Hz,3H),1.27-1.39(m,2H)。
实施例十二、产品编号TMI-105960
命名:
N1-(3,5-二氯-4-(4-羟基-3-((4-羟基-4-苯基哌啶-1-甲基)苯氧基)苯基)N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:10.63(br.s.,1H),8.10(s,2H),7.22-7.32(m,2H),7.10-7.22(m,3H),6.57-6.68(m,2H),6.51(dd,J=8.6,3.0Hz,1H),3.35(br.s.,2H),2.82(d,J=10.7Hz,2H),1.96(t,J=11.1Hz,2H),1.43-1.68(m,2H),1.09-1.26(m,2H)。
实施例十三、产品编号TMI-105961
命名:
N1-(3,5-二氯-4-(4-羟基-3-(异吲哚啉-2-甲基)苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:8.09(s,2H),7.07-7.36(m,4H),6.64-6.82(m,4H),6.56(dd,J=8.5,3.4Hz,2H),3.79-3.91(m,4H),1.33(d,J=4.8Hz,2H),
实施例十四、产品编号TMI-105962
命名:
N1-(3,5-二氯-4-(3-(3,4-二氢异喹啉-2(1H)-甲基)-4-羟基苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:10.03(br.s.,1H),8.05-8.16(m,1H),7.62(s,1H),7.08-7.17(m,2H),7.04(d,J=5.4Hz,1H),6.49-6.76(m,4H),3.83(s,1H),3.71(s,2H),3.63(s,2H),2.79(d,J=5.6Hz,2H),2.57-2.75(m,2H)
实施例十五、产品编号TMI-105963
命名:
N1-(3,5-二氯-4-(4-羟基-3-(3-哌嗪酮-1-甲基)苯氧基)苯基)-N2-草酰羟胺
结构式:
产物谱图数据:
1HNMR(DMSO-d6)δ:8.07-8.15(m,2H),7.76(s,1H),6.66-6.76(m,2H),6.58(dd,J=8.7,3.1Hz,1H),3.53(s,2H),3.17(s,2H),3.11(br.s.,2H),2.96(s,2H),1.06(t,J=7.0Hz,2H)
本实施例的作用和效果:
A.小鼠试验:本实验选用的检测待测化合物为TMI-105795。
一、材料和方法
本实验根据以下描述的步骤和细节进行操作,据我们所知,在实验研究过程中,没有任何影响数据的质量和完整性的情况发生。
(1)待测物
受试化合物(TMI-105795)由药学部分装后保存于-20℃冰箱中。所有受试化合物(包括溶剂)标记成TDM-001-1,TDM-001-2,TDM-001-3,TDM-001-4。
(2)实验动物
雌性C3H小鼠(达到时35-39日龄)购买于北京维通利华实验动物技术有限公司。将健康干净的小鼠挑选出来作为实验用鼠。分组前,将随机的5只小鼠一笼饲养,所有的小鼠在动物房里至少适应性饲养一周,动物的标记分别标记在尾巴上和笼盒上。
(3)动物饲养
整个实验过程,将所有小鼠(单只每笼饲养)分别饲养在不同组别中,笼盒内垫有柔软垫料(玉米芯或木屑),以保持饲养环境的统一。自由摄取水和食物,保持饲养间的湿度(50-70%)和温度(21-25℃)稳定,且保持12小时明暗循环周期。
(4)给药
待测化合物为TMI-105795(溶剂为聚乙二醇/乙醇(30/70)),分装成为每日给药量保存在-20℃冰箱里。和溶剂一起经皮每天上午9:30和下午4:00给药两次。
(5)实验设计
(6)行为学观察
每天均需检查小鼠的异常行为表现和毛发生长情况,并仔细记录下来。
(7)体重
实验过程中,每只小鼠每天给药前都要称量体重。
(8)评分
从实验开始的第一天到最终结束,每周一、周三和周五对毛发生长级别,外周毛发生长,皮屑,红斑这些现象进行评分。
二、试剂,耗材,设备
(1)待测物(TMI-105795)
(2)Eppendof移液器
(3)100μl枪头,灭菌
(4)小动物剃毛器
三、实验过程
(1)分组
用小动物剃毛器,小心仔细的将小鼠后腿背部的毛剃掉,注意避免损伤小鼠背部皮肤。再次确认小鼠背部皮肤的颜色,所有的小鼠应该是粉红色皮肤,任何皮肤有损伤的小鼠都应当从实验中剔除。随机的将小鼠分成五组,并单只饲养。
(2)给药流程
每天上午给药前,记录每只小鼠的体重。用移液器吸取20μL相应的溶液涂于小鼠背部剃毛区,然后用枪头把药液均匀涂于后腿间的背部,大约为直径1厘米的区域。确保每天给药的区域是同一个区域,并等待药液干燥之后再放入笼盒中。
(3)评分流程
所有小鼠依据以下标准,在实验开始的第一天到最后一天中的每周一、周三和周五进行毛发生长评分:
a.毛发生长等级(给药区域):
0=皮肤没有颜色改变,或者毛发生长;
1=皮肤颜色均匀改变:给药区由粉红色变成灰/黑色,但无毛发生长;
2=出现短而稀疏的毛发生长;
3=浓密的毛发生长,同周围未剃毛区域一样。
b.外周毛发生长(剃毛区的毛发生长,而不是给药区的毛发生长):
0=皮肤没有颜色改变,或者毛发生长;
1=皮肤颜色改变成灰/黑色但没有毛发生长;
2=外周区域稀疏毛发生长;
3=外周区域浓密毛发生长。
c.皮屑:
0=无
1=轻微
2=严重或脱皮
d.红斑:
0=无(正常皮肤)
1=轻微
2=严重
e.其他异常情况(待测物在给药区的沉积,杂乱的毛发生长,等等)
四、试验结果
(1)、实验过程中小鼠状态
a.如图1(a)-(d)所示,给药3周后,和溶剂的空白对照组相比,待测物(TMI-105795)的所有剂量均表现出明显的毛发生长促进作用。溶剂对照组没有发现明显的毛发生长。
b.如图1(a)-(d)所示,待测化合物的不同剂量也出现了明显的剂量依赖,高剂量的待测化合物对毛发生长的促进作用明显强于低剂量的。如图18所示,根据给药过程中各小鼠毛发生长的评分结果可以看出,空白溶剂对照组始终无变化,TDM-001-2(即、0.005%(w/v))浓度组相较于TDM-001-3(即、0.01%(w/v))浓度组和TDM-001-4(即、(0.05%(w/v))浓度组有明显的差异。
针对不同浓度的给药小鼠实验组来看,其毛发生长的速度差异明显,其中,TDM-001-2增长的速度远低于TDM-001-3和TDM-001-4的速度。
具体表现为:TDM-001-2的小鼠经皮用药后,第12天小鼠皮肤颜色变黑,16天后可见毛发开始生长,并持续生长。
TDM-001-3的小鼠经皮用药后,第2天小鼠皮肤颜色变黑,6天后可见毛发开始生长,并持续生长。
TDM-001-4的小鼠经皮用药后,第2天小鼠皮肤颜色变黑,8天后可见毛发开始生长,并持续生长。
由此可以看出,低浓度的给药小鼠的生长速度和生长水平明显低于高浓度的给药小鼠的生长速度和水平,而当浓度达到0.01%时,虽然其毛发生长的过程存在一定差异,但当其发毛的生长达到一定水平时,毛发生长的情况和状态差异不再明显。
c.如图17所示,每组中的小鼠体重增加的都很缓慢,表明受试化合物不会引起动物体重减少。
d.如图19和20所示,每组中的小鼠都未出现皮屑和红斑现象。
(2)、评价结果汇总
a.包括最低剂量的受试化合物都表现出阳性的促进毛发生长的效果。
b.所有小鼠都未出现皮屑和红斑现象。
除了以上出现的情况,所有小鼠均表现出正常的皮肤颜色和症状表现。
五、本实施例的结论
待测物TMI-105795明显地促进了C3H小鼠的毛发生长。
C3H小鼠背部毛发已知具有时间对应的毛发生长周期,即、2.5到3.5周龄和5到14周龄其背部毛发处于毛发生长终期(休眠期),0到2.0周龄和4.0到4.5周龄其背部毛发处于毛发生长初期。
本实验中,检测了待测物(TMI-105795)对C3H小鼠毛发生长的影响。经皮给药三周后,和溶剂对照组相比,待测物(TMI-105795)的不同剂量都表现出毛发生长促进作用。同时,待测物的三个不同剂量也表现出了明显的剂量依赖。
故而,本实验结果显示待测物(TMI-105795)能明显的改变毛发生长周期,促进毛发生长。
此处值得指出,其他几种实施例中的化合物也能产生近似的效果,此处不再做冗余的描述。
B:甲状腺受体TRβ激动剂实验
一、具体试验方法:
1、细胞铺板:
1)细胞铺板之前2小时,96孔板加入40微升多聚-D-赖氨酸,室温包被。
2)移除多聚-D-赖氨酸。96孔板每孔加入4*104个HEK-293细胞,使用含10%胎牛血清的DMEM培养基在37摄氏度细胞培养箱培养过夜。
2、共转染:
1)转染之前2小时,移除细胞培养基。每孔加入100微升含10%活性炭处理胎牛血清的DMEM培养基,37摄氏度培养箱孵育2小时。
2)制备质粒DNA-XtremeGENEHP脂质体复合物。
①转染试剂X-tremeGENEHP用前室温复温,轻微涡旋混匀。
②在无菌试管中加入Opti-MEMI减血清培养基。
③每个反应体系加入50纳克甲状腺受体(TRβ)质粒DNA和50纳克甲状腺激素应答元件(TRE)质粒DNA。轻微吹打使之完全混匀。
④将0.2微升转染试剂X-tremeGENEHP加入稀释的共转DNA混合物。轻微吹打使之完全混匀。
⑤在室温中孵育20分钟,进而形成质粒DNA-XtremeGENEHP脂质体复合物。
3)96孔板每孔加入10微升复合物。轻微摇动培养板使复合物均匀分散。
4)37度培养箱孵育24小时。
3、激动剂化合物处理:
1)配制化合物稀释液:用含10%活性炭处理胎牛血清的DMEM培养基(含0.1%二甲亚砜)将待测化合物逐步进行半对数稀释,待测化合物的最高浓度为10微摩。
2)移除细胞培养基,加入配置的化合物稀释液(二甲亚砜最终浓度为0.1%)。
3)对于空白对照,加入含10%活性炭处理胎牛血清的DMEM培养基(含0.1%二甲亚砜)。
4)37摄氏度培养箱孵育24小时。
4、荧光素酶报告基因检测:
1)移除培养基,每孔加入40微升磷酸缓冲液。
2)每孔加入40微升Bright-Glo试剂,震荡30秒。避光孵育2分钟。
3)将每孔70微升细胞裂解物加入白色聚苯乙烯96孔板。
4)用EnVision检测荧光信号。
二、试验结果:(如图2-7所示)
编号 | EC50(nM) |
105796 | 179.4 |
TMI-105902 | 250.3 |
TMI-105903 | 136.4 |
TMI-105905 | 399.5 |
TMI-105965 | 95.97 |
TMI-105966 | 61.13 |
TMI-105906 | 925.4 |
TMI-105956 | 6521 |
TMI-105957 | 8757 |
TMI-105958 | 9701 |
TMI-105959 | 617.2 |
TMI-105960 | 6.478E7 |
TMI-105961 | 9243 |
TMI-105962 | 3719 |
TMI-105963 | 9577 |
Claims (9)
1.一种小分子化合物,其特征在于,由如下结构式所示:
R1选自氢、C0-C6的烷基,不包括C0烷基,或其任意地被一个到三个取代基取代,其中,所述取代基选自于卤素、芳基;
R2选自氢、卤素;
R3选自氢、卤素;
R4选自氢;
R5选自氢;
X选自胺基;
Y选自氧。
2.如权利要求1所述的一种小分子化合物,其特征在于,由如下结构式所示:
其中,R为单取代或多取代的卤素、烷基磺酰基、甲氧基、羟基、氢。
3.一种小分子化合物,其特征在于:为N1-(3,5-二氯-4-(3-(4-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(3-(4-甲磺酰基苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(3-(4-甲基苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(3-(3,4-二氯苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(3-(3-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(3-(2-氟苄基)-4-羟基苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(4-羟基-3-(甲基吗啉)苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(4-羟基-3-(4-羟基哌啶-1-基)苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(4-羟基-3-(4-甲基哌嗪-1-甲基)苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(4-羟基-3-(吡咯烷-1-甲基)苯氧基)苯基)-N2-草酰羟胺;或
N1-(4-(3-((4-苄基哌啶-1-甲基)-4-羟基苯氧基)-3,5-二氯苯基)N2-草酰羟胺;或
N1-(3,5-二氯-4-(4-羟基-3-((4-羟基-4-苯基哌啶-1-甲基)苯氧基)苯基)N2-草酰羟胺;或
N1-(3,5-二氯-4-(4-羟基-3-(异吲哚啉-2-甲基)苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(3-(3,4-二氢异喹啉-2(1H)-甲基)-4-羟基苯氧基)苯基)-N2-草酰羟胺;或
N1-(3,5-二氯-4-(4-羟基-3-(3-哌嗪酮-1-甲基)苯氧基)苯基)-N2-草酰羟胺。
4.如权利要求1所述的一种小分子化合物的合成方法,其特征在于:
步骤一、通过4-甲氧基苯酚与1,2,3-三氯-5-硝基苯反应生成1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯;
步骤二、将1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯与苯甲酸衍生物反应生成(5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(取代苯基)甲基酮;
步骤三、将(5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(取代苯基)甲基酮的羰基还原为亚甲基得到1,3-二氯-2-(3-(取代苄基)-4-甲氧基苯氧基)-5-硝基苯;
步骤四、将1,3-二氯-2-(3-(取代苄基)-4-甲氧基苯氧基)-5-硝基苯的硝基还原为氨基后得到3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯胺;
步骤五、将3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯胺与草酰氯单乙酯反应生成2-((3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯;
步骤六、将2-((3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯与盐酸羟胺反应生成N1-(3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)-N2-草酰羟胺;
步骤七、将N1-(3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)-N2-草酰羟胺上的甲氧基脱甲基后获得目标小分子化合物。
5.如权利要求4所述的一种小分子化合物的合成方法,其特征在于:
步骤一中4-甲氧基苯酚与1,2,3-三氯-5-硝基苯的摩尔比为1:1-2;
步骤二中1,3-二氯-2-(4-甲氧基苯氧基)-5-硝基苯与苯甲酸衍生物的摩尔比为1:1.25-2;
步骤四中1,3-二氯-2-(3-(取代苄基)-4-甲氧基苯氧基)-5-硝基苯与还原剂的摩尔比为1:10-20;
步骤五中3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯胺与草酰氯单乙酯的摩尔比为1:1.5-3;
步骤六中2-((3,5-二氯-4-(3-(取代苄基)-4-甲氧基苯氧基)苯基)胺基)-草酰乙酯与盐酸羟胺的摩尔比为1:5-10。
6.如权利要求4所述的一种小分子化合物的合成方法,其特征在于:
步骤一在强碱条件下进行,
所述强碱可选自氨基钾、氨基钠、***、***、丁基锂、二异丙基氨锂、苄基锂、格氏试剂,烷基铜锂、甲醇钠、乙醇钠、乙醇钾、叔丁醇钠、氢氧化钠、氢氧化钾,反应温度为120-160℃;
步骤二在伊顿试剂中进行,反应温度为80-130℃。
7.如权利要求4所述的一种小分子化合物的合成方法,其特征在于:步骤三中采用三氟乙酸和三乙基硅烷将羰基还原为亚甲基,
其中,5-(2,6-二氯-4-硝基苯氧基)-2-甲氧基苯基)(取代苯基)甲基酮:三氟乙酸:三乙基硅烷的摩尔比为1:4-6:3-5。
8.如权利要求4所述的一种小分子化合物的合成方法,其特征在于:步骤七中的脱甲基可采用三氯化铝、氯化锌、三溴化硼进行。
9.如权利要求1-3任一所述的一种小分子化合物用于制造应用于毛发的再生、骨质疏松症、肥胖的药物上的应用。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410398184.1A CN104193699B (zh) | 2014-08-14 | 2014-08-14 | 一种小分子化合物及其合成方法和应用 |
DK15831295.9T DK3181556T5 (da) | 2014-08-14 | 2015-08-13 | Mikromolekyleforbindelse, fremgangsmåde til syntese og anvendelse deraf |
EP15831295.9A EP3181556B1 (en) | 2014-08-14 | 2015-08-13 | Micromolecule compound, method of synthesis and application thereof |
PCT/CN2015/086908 WO2016023510A1 (zh) | 2014-08-14 | 2015-08-13 | 一种小分子化合物及其合成方法和应用 |
JP2017502885A JP6444487B2 (ja) | 2014-08-14 | 2015-08-13 | 小分子化合物、その合成方法、及びその応用 |
HUE15831295A HUE057149T2 (hu) | 2014-08-14 | 2015-08-13 | Mikromolekula vegyület, eljárás szintézisére és alkalmazására |
US15/431,779 US9920022B2 (en) | 2014-08-14 | 2017-02-14 | Small molecule compound and synthesizing method and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410398184.1A CN104193699B (zh) | 2014-08-14 | 2014-08-14 | 一种小分子化合物及其合成方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104193699A CN104193699A (zh) | 2014-12-10 |
CN104193699B true CN104193699B (zh) | 2016-05-25 |
Family
ID=52079108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410398184.1A Active CN104193699B (zh) | 2014-08-14 | 2014-08-14 | 一种小分子化合物及其合成方法和应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9920022B2 (zh) |
EP (1) | EP3181556B1 (zh) |
JP (1) | JP6444487B2 (zh) |
CN (1) | CN104193699B (zh) |
DK (1) | DK3181556T5 (zh) |
HU (1) | HUE057149T2 (zh) |
WO (1) | WO2016023510A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104193699B (zh) * | 2014-08-14 | 2016-05-25 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物及其合成方法和应用 |
CN104877136B (zh) * | 2015-04-30 | 2017-08-01 | 大连理工大学 | 一种长支链聚砜阴离子膜及其制备方法 |
CN105461588A (zh) * | 2015-12-17 | 2016-04-06 | 上海海洋大学 | 一种立达霉中代谢产物6的合成方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103479627A (zh) * | 2013-05-16 | 2014-01-01 | 武汉光谷百桥国际生物科技有限公司 | 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69314718T2 (de) * | 1992-07-21 | 1998-02-26 | Ciba Geigy Ag | Oxamidsäure-Derivate als hypocholesterämische Mittel |
DE60012700T2 (de) * | 1999-03-01 | 2005-07-28 | Pfizer Products Inc., Groton | Oxamsäure und deren derivate als liganden der thyroid-rezeptoren |
CO5160290A1 (es) * | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
AU3507700A (en) * | 1999-06-01 | 2000-12-18 | University Of Texas Southwestern Medical Center, The | Method of treating hair loss using diphenylether derivatives |
WO2001070687A1 (de) * | 2000-03-23 | 2001-09-27 | Bayer Aktiengesellschaft | Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können |
DE10024939A1 (de) * | 2000-05-19 | 2001-11-29 | Bayer Ag | Neue Diphenylmethanderivate für Arzneimittel |
GB2374009A (en) * | 2001-02-12 | 2002-10-09 | Novartis Ag | Method of treating hair loss |
CN104193699B (zh) * | 2014-08-14 | 2016-05-25 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物及其合成方法和应用 |
-
2014
- 2014-08-14 CN CN201410398184.1A patent/CN104193699B/zh active Active
-
2015
- 2015-08-13 WO PCT/CN2015/086908 patent/WO2016023510A1/zh active Application Filing
- 2015-08-13 JP JP2017502885A patent/JP6444487B2/ja active Active
- 2015-08-13 DK DK15831295.9T patent/DK3181556T5/da active
- 2015-08-13 HU HUE15831295A patent/HUE057149T2/hu unknown
- 2015-08-13 EP EP15831295.9A patent/EP3181556B1/en active Active
-
2017
- 2017-02-14 US US15/431,779 patent/US9920022B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103479627A (zh) * | 2013-05-16 | 2014-01-01 | 武汉光谷百桥国际生物科技有限公司 | 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3181556A1 (en) | 2017-06-21 |
US9920022B2 (en) | 2018-03-20 |
WO2016023510A1 (zh) | 2016-02-18 |
DK3181556T3 (da) | 2022-01-03 |
DK3181556T5 (da) | 2022-01-10 |
JP6444487B2 (ja) | 2019-01-09 |
JP2017522329A (ja) | 2017-08-10 |
US20170158651A1 (en) | 2017-06-08 |
HUE057149T2 (hu) | 2022-04-28 |
CN104193699A (zh) | 2014-12-10 |
EP3181556A4 (en) | 2018-01-10 |
EP3181556B1 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104193699B (zh) | 一种小分子化合物及其合成方法和应用 | |
ES2316736T3 (es) | Moduladores de receptores activados por proliferador de peroxisoma. | |
US9034850B2 (en) | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | |
JP2018062535A (ja) | ガンの治療方法 | |
CN1265033A (zh) | 二芳基咪唑衍生物:新的一类npy特异性配体 | |
CN101065352A (zh) | 使用新的三氟甲磺酰苯胺肟醚衍生物控制动物中的寄生虫 | |
AU2005285035A1 (en) | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | |
US20120302609A1 (en) | Pyrazolines for the Modulation of PKM2 | |
BRPI0712301A2 (pt) | composto, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto | |
CN110099900A (zh) | 针对Smoothened突变株的刺猬通路抑制剂 | |
US20200113913A1 (en) | Methods for hair follicle stem cell proliferation | |
CN105237444B (zh) | 异羟肟酸类化合物及其制备方法和用途 | |
CA2822923A1 (en) | A process for the preparation of lapatinib and its ditosylate salt | |
US9920056B2 (en) | 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives | |
CA2947912C (en) | 2,2'-bis-thiazole-based compounds, preparation method therefor and use thereof | |
Rüger et al. | Synthesis of tetra-substituted pyrazoles | |
JP2010159260A (ja) | リパーゼ阻害活性をもったチエノ−(1,3)−オキサジン−4−オン類 | |
US20220339260A1 (en) | Method for producing insulin-producing cell using dihydroindolizinone derivatives | |
JP2019518715A (ja) | ベンゼンスルホニル非対称尿素とその医学的利用 | |
CN105481779A (zh) | 抗癌药物Rociletinib及其中间体制备 | |
EP3180001B1 (en) | Active metabolite of 1-[(2-bromophenyl) sulfonyl]-5-methoxy-3- [(4-methyl-1-piperazinyl) methyl]-1h-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite | |
Smolobochkin et al. | Synthesis of Novel Tetrahydropyrimidines via the Reaction of Sodium [1-(3, 3-Diethoxypropyl) ureido] methanesulfonates with C-Nucleophiles | |
Abbasi et al. | N-Sulfonated Derivatives of 2, 3-Xylidine as Suitable Antibacterial Agents. | |
RU2560178C1 (ru) | Способ получения 3-замещенных 2-(3-феноксифенил)акрилонитрилов | |
US10092574B2 (en) | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |